ArticleBMC medicine2025
Prenatal lipopolysaccharide exposure programs the early-life lung development by modulating mesenchymal fibroblasts in a time- and dose-dependent manner.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mesenchymal Stem Cell (MSC)-based therapies for neonatal lung and brain injury - one size fits all?Molecular and cellular pediatrics · 2026Review
- Epigenetic programming in bronchopulmonary dysplasia: a framework linking early-life exposures to persistent lung disease-a narrative review.Pediatric research · 2026Review
- Prenatal non-infectious mild stressor modulates early-life lung development in a time-specific manner.Respiratory research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundBronchopulmonary dysplasia (BPD) is one common and severe complication of preterm births. Prenatal infection/inflammation is the major cause driving preterm deliveries, but its contribution to the early-life lung development remains unclear.
methodsPregnant C57BL/6J mice were randomized at 15.5 or 18.5 days post coitum (dpc) to receive intraperitoneal injection of sterile saline, lipopolysaccharide (LPS) 50 μg/kg, or LPS 100 μg/kg. Animal experiments were performed compliantly to the ARRIVE guidelines. Lungs of newborn pups of mixed genders were harvested at the first postnatal day (P1) for histopathology to investigate prenatal LPS-induced structural changes. Expression of key pro- and anti-inflammatory mediators was assessed at both transcriptional and translational levels. Based on bulk RNA sequencing and exploratory transcriptomic analysis, signature gene and phenotypical expression of two major mesenchymal fibroblasts subsets, myofibroblasts (MYFs) and lipofibroblasts (LIFs), were analyzed with qPCR, immunofluorescence, and western blot. Human embryo-derived WI-38 fibroblast cell line was used as an in vitro model to investigate LPS-induced fibroblast inflammatory responses and MYFs-LIFs differentiation.
resultsNewborn mice exposed to prenatal LPS exhibited enlarged air spaces and thinner septal walls, with an enhanced interleukin 6 (IL6) response in lung tissues. The degree of lung structural changes is LPS dose- and timing-dependent. Exploratory transcriptomic analysis revealed the enrichment in myofibrogenic pathways in LPS-exposed lungs. Platelet-derived growth factor receptor alpha (PDGFRA)-expressing progenitor lung fibroblasts were generally suppressed by prenatal LPS exposure. The expression of MYFs signature markers (ELN and ACTA2) in relation to LIFs (PLIN2 and FGF10) demonstrated a highly heterogeneous and dynamic pattern, depending on LPS doses and timing. Upon LPS exposure, human WI-38 fibroblasts upregulated a panel of pro-inflammatory mediators via nuclear factor kappa B signaling and displayed diverse MYFs and LIFs differentiation depending on the dose and duration of LPS stimulation.
conclusionsPrenatal LPS exposure induces heterogeneous structural and molecular changes in the newborn mice lung, showing LPS dose- and time-dependent modulation of mesenchymal fibroblast differentiation. These findings may contribute to refine the risk stratification of preterm infants exposed to prenatal infection/inflammation. Mesenchymal fibroblast plasticity and MYFs-LIFs phenotypic shifts may inspire preventive and therapeutic strategies for BPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.